Inozyme Pharma, Inc. (INZY)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Inozyme Pharma, Inc. (INZY)
Company Performance

Current Price

as of Oct 16, 2024

$5.31

P/E Ratio

N/A

Market Cap

$333.12M

Description

Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. It engages in the business of developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company was founded by Axel Bolte, Joseph P. Schlessinger, and Demetrios T. Braddock in September 2015 and is headquartered in Boston, MA.

Metrics

Overview

  • HQBoston, MA
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerINZY
  • Price$5.31-1.12%

Trading Information

  • Market Cap$333.12M
  • Float67.94%
  • Average Daily Volume (1m)201,203
  • Average Daily Volume (3m)246,610
  • EPS-$1.46

Company

  • RevenueN/A
  • Rev Growth (1yr)N/A
  • Net Income-$27.03M
  • Gross MarginN/A
  • EBITDA MarginN/A
  • EBITDA-$27.48M
  • EV$178.46M
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
  • P/B3.49
Documents